Yann Mazabraud - 02 Mar 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Reporting relationship: EVP, Head of International
Issuer ticker: RYTM
Reported as of: 02 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Mar 2026, 20:22:48 UTC
Prior SEC filing: 18 Feb 2026
Next SEC filing: 03 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephen Vander Stoep, attorney-in-fact for Yann Mazabraud

Key filing fact

Yann Mazabraud filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 04 Mar 2026.

Key facts

This page summarizes Yann Mazabraud's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Mar 2026, 20:22.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001774702 Primary reporting owner

Mazabraud Yann

Relationship: EVP, Head of International
Address: 222 BERKELEY STREET, 12TH FLOOR, BOSTON
Signature: /s/ Stephen Vander Stoep, attorney-in-fact for Yann Mazabraud
Signature date: 04 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYTM transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value
Shares: +35,000
Change %
Price: $0.000000^*
Shares after: 35,000
Date: 02 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $94.94
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock options were granted on March 2, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.